Skip to content
Advertisement

FILE - In this Monday, Dec. 21, 2020 file photo, under the watchful eye of Prof. Dr. Iftahar Koksal, left, nurse Arzu Yildirim, center, administers a dose of the CoronaVac vaccine, made by Sinovac, currently on phase III clinical trials at Acibadem Hospital in Istanbul. The experimental COVID-19 vaccine developed by the Chinese biopharmaceutical company is 91.25% effective, a Turkish health official said on Thursday, Dec. 24. The efficacy rate announced by Turkey could not be immediately verified independently. Turkey, which has has among the worst infection rates in the world. has signed a deal for 50 million doses of the vaccine. (AP Photo/Emrah Gurel, File)

FILE - In this Monday, Dec. 21, 2020 file photo, under the watchful eye of Prof. Dr. Iftahar Koksal, left, nurse Arzu Yildirim, center, administers a dose of the CoronaVac vaccine, made by Sinovac, currently on phase III clinical trials at Acibadem Hospital in Istanbul. The experimental COVID-19 vaccine developed by the Chinese biopharmaceutical company is 91.25% effective, a Turkish health official said on Thursday, Dec. 24. The efficacy rate announced by Turkey could not be immediately verified independently. Turkey, which has has among the worst infection rates in the world. has signed a deal for 50 million doses of the vaccine. (AP Photo/Emrah Gurel, File)

Featured Photo Galleries